Agoracom Blog Home

Posts Tagged ‘stocks’

Else Nutrition $BABY.ca Announces an Increase to Previously Announced Bought Deal Public Offering – $18M CAD Gross Proceeds + Up to $6M CAD Via Private Placement $KMB $BMY $ABT $WYE

Posted by AGORACOM-JC at 2:16 PM on Wednesday, September 16th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • Underwriters have agreed to purchase, on a bought deal basis, an aggregate of 8,000,000 units of the Company at a price of C$2.25 per Unit for aggregate gross proceeds to the Company of C$18 million
  • In addition to the Offering, the Company is increasing the size of its previously announced non-brokered private placement to up to 2,666,666 Units at the Offering Price for gross proceeds to the Company of up to C$6 million

VANCOUVER, BC, Sept. 16, 2020 – Else Nutrition Holdings (TSXV: BABY) (OTCQX: BABYF) (FSE: 0YL) (“Else” or the “Company”), is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. on behalf of a syndicate of underwriters (the “Underwriters”) pursuant to which the Underwriters have agreed to increase the size of its previously announced bought deal financing. The Underwriters have agreed to purchase, on a bought deal basis, an aggregate of 8,000,000 units (the “Units”) of the Company at a price of C$2.25 per Unit (the “Offering Price”) for aggregate gross proceeds to the Company of C$18 million (the “Offering”).

Each Unit shall consist of one common share (each a “Common Share”) and one-half of one common share purchase warrant of the Company (each whole common share purchase warrant, a “Warrant”). Each Warrant shall be exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 24 months from closing of the Offering at an exercise price of C$3.25 per Warrant, subject to adjustment in certain events.

The Company has granted the Underwriters an option (the “Over-Allotment Option”) to purchase up to an additional 1,200,000 Units at the Offering Price, which Over-Allotment Option will be exercisable at any time and from time-to-time, for a period of 30 days following the Closing Date (as defined below), which would result in additional gross proceeds of C$2.7 million. The Over-Allotment Option is exercisable to acquire Units, Common Shares and/or Warrants (or any combination thereof) at the discretion of the Underwriters.

The Units will be offered by way of a short form prospectus to be filed in all provinces of Canada except Quebec and elsewhere on a private placement basis. The Offering is expected to close on October 6, 2020 (the “Closing Date”) and is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the TSX Venture Exchange and the applicable securities regulatory authorities.

In addition to the Offering, the Company is increasing the size of its previously announced non-brokered private placement to up to 2,666,666 Units at the Offering Price for gross proceeds to the Company of up to C$6 million (the “Concurrent Private Placement”).  No commission or finder’s fee is payable to the Underwriters in connection with the Concurrent Private Placement.

The Company intends to use the proceeds of the Offering for marketing, distribution, inventory and general corporate purposes.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.

About Else Nutrition Holdings Inc.
Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan.

The holding company, Else Nutrition Holdings Inc, is a publicly traded company, listed on the TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

TSX Venture Exchange
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements
This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include, but are not limited to, statements relating to the timing and ‎completion of the Offering, the satisfaction and timing of the receipt of required stock exchange ‎approvals and other conditions to closing of the Offering and the intended use of the net proceeds of ‎the Offering. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE Else Nutrition Holdings Inc.

Ms. Hamutal Yitzhak, CEO, Co-Founder & Director, ELSE Nutrition Holdings Inc., E: [email protected], P: +972(0)3-6445095; Mr. Sokhie Puar, Director, ELSE Nutrition Holdings Inc., E: [email protected], P: 604-603-7787Copyright CNW Group 2020

VIDEO: Innocan $INNO.ca Completes Successful Cosmetic Clinical Studies Demonstrating the Efficacy of Its SHIR(TM) #CBD Premium Facial Serum on Skin Hydration $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 12:15 PM on Wednesday, September 16th, 2020
Innocan-Blog

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) has completed a cosmetic clinical study examining the impact of its SHIR ™ Premium CBD Facial Serum containing 300 mg of cannabidiol (“CBD“) on skin hydration.

  • Study was conducted by an independent research laboratory: INOVAPOTEK, Pharmaceutical Research and Development in Portugal”.
  • The study aimed to assess the hydrating efficacy of the Serum in vivo, by measuring the skin capacitance for a period of 2, 4, 8 and 24 hours after the CBD Serum application on the skin.
  • The results demonstrated that there were significant hydration increases for each period.
  • The Serum was well tolerated with no uncomfortable symptoms or feelings reported by the subjects of the study.

In addition, the research laboratory completed a clinical controlled study for the evaluation of the acute cutaneous irritation potential of cosmetic products. All of the SHIR™ Derma Cosmetic products tested to date have demonstrated to be non-irritating under the test conditions.

Read Full Release

Berkeley Opens Its Mind to Psychedelics with New Research Centre SPONSOR: Red Light Holland $TRIP.ca $SHRM.ca $RVV.ca

Posted by AGORACOM at 9:57 AM on Wednesday, September 16th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564679/hub/Red_Light_Holland_Logo_2.png

Sponsor: Red Light Holland’s goal is to grow, distribute and market a premium brand of magic truffles to the legal, recreational market within the Netherlands, and we can’t wait to shift the existing paradigm to direct further attention to the legal and responsible use of magic truffles. Click Here For More Info

The University of California at Berkeley is getting the dirt on mushrooms.

The school announced on Monday that it will be launching the UC Berkeley Center for the Science of Psychedelics — an institute devoted to expanding and better understanding the effects hallucinogens have on the human brain, according to Marijuana Moment.

“There’s never been a better time to start a centre like this,” said neuroscientist David Presti, one of the founding members of the project. “The renewal of basic and clinical science with psychedelics has catalyzed interest among many people.”

Buoyed by an anonymous US$1.2-million donation, the centre will begin its research by looking at psilocybin — the hallucinogenic component of mushrooms that has received increased attention at other institutions recently for its ability to treat conditions previously thought untreatable.

“Some of these studies have produced striking results in cases that are otherwise resistant to more conventional medical treatment,” said Michael Silver, a neuroscientist and the director of the new centre. “This suggests that psychedelic compounds may offer new hope for people suffering from these disorders.”

Researchers are also working with the university’s graduate theological union to train students to be “facilitators” during psychedelic ceremonies with a focus on the “cultural, contemplative and spiritual care dimensions of psychedelics.”

Study at the centre will be geared toward understanding what happens in the human brain during a psychedelic experience. Researchers hope to gain insight into how visual hallucinations manifest themselves in the brain and the effect they have on a person’s identity, ability to cope with stress and even their social and political attitudes.

“Psychedelic medicines can open a doorway to seeing one’s psyche and connection with the world in new and helpful ways,” Presti said. “That’s been appreciated by shamanic traditions for thousands of years. Science is now exploring new ways to investigate this.”

Currently, psilocybin mushrooms are classified as a Schedule I drug by the FDA, the same category as heroin and cannabis. To be a Schedule I drug means the substance in question holds no medicinal value. As researchers find mushrooms have a positive effect on anxietytreatment-resistant depression, and Seasonal Affective Disorder, that could change.

Like cannabis, psilocybin has a long track record of relative safety among recreational users, and it is not toxic. Unlike some drugs that treat anxiety and other mental conditions, psilocybin is not prone to dependence. But given its hallucinogenic effect, lawmakers may be reticent to allow distribution of the psychedelic drug without more restrictions.

SOURCE: https://theprovince.com/wellness/berkeley-opens-its-mind-to-psychedelics-with-new-research-centre/wcm/3ae4ae9e-7f88-42cf-9e17-ba77318dd03c/

PK Beans $BEAN.ca Launches Rebranded Fall Collection to Record-Breaking Response

Posted by AGORACOM-JC at 9:28 AM on Wednesday, September 16th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564687/hub/PK_beans.jpg
  • Since pivoting the business model, the Company has strategically been growing its online presence and receiving notable return on ad-spend (ROA) metrics
  • With that, the Company saw a 900% increase of sales on launch day over Fall 2019, of $36,000 and a 25% inventory sell through within the first two weeks
  • Numbers indicate a strong positive reception of the Company’s modern Rebrand and quality selection of age-appropriate, comfortable and fashion forward clothing for Boys, Girls and Babies; just in time for the ‘back to school’ season
  • PK Beans’ Fall 2020 Collection features an expanded size range from 0-3 months through to size 12 and new gender-neutral styles of hoodies and denim

Vancouver, British Columbia–(September 16, 2020) – Peekaboo Beans Inc. (CSE: BEAN) (OTC Pink: PBBSF) (“PK Beans” or the “Company”) a responsible and innovative children’s apparel brand is pleased to report the successful launch of its first ever rebranded product in August. Since pivoting the business model, the Company has strategically been growing its online presence and receiving notable return on ad-spend (ROA) metrics. With that, the Company saw a 900% increase of sales on launch day over Fall 2019, of $36,000 and a 25% inventory sell through within the first two weeks.

These numbers indicate a strong positive reception of the Company’s modern Rebrand and quality selection of age-appropriate, comfortable and fashion forward clothing for Boys, Girls and Babies; just in time for the ‘back to school’ season. PK Beans’ Fall 2020 Collection features an expanded size range from 0-3 months through to size 12 and new gender-neutral styles of hoodies and denim.

In addition to a successful Fall launch; the Company continues to gain margin momentum through new inventory coming and their growing sustainable PK RePlay initiative, and partnerships with local manufacturers supplying masks for children and adults adapting to COVID-19 demands. The Company has also started a new Wholesale program to further expand their omni-channel business model, brand awareness and customer-reach.

“We strategically pivoted PK Beans to grow multiple sales channels,” says CEO and Founder, Traci Costa. “We have the most loyal customers with our 50% returning customer rate, and a significantly higher than industry average ROA. Combined with our strong mission of happy and healthy children, we are now poised to be an industry leader in bridging the gap of children’s fashion and their healthy growth and development.”

About Peekaboo Beans Inc.

PK Beans is an innovative children’s apparel brand with a focus on environmentally responsible clothes that are intentionally designed to inspire play. Through an omni-channel approach, Peekaboo Beans engages sellers through social platforms, including Instagram and Facebook, as well as online retailers, to maximize revenue and build brand loyalty. The Company works to promote a playful lifestyle for children by designing comfortable clothes that are built to last.

To learn more about PK Beans, visit: www.pkbeans.com.

On behalf of the Board of Directors,
Peekaboo Beans Inc.

Ms. Traci Costa, President and CEO
(604) 279-2326

For more information, please contact the Company at:
[email protected]
1-604-279-2326

Reader Advisory

This news release may include forward-looking information that is subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking. Although the Company believes the expectations expressed in such forward-looking information are based on reasonable assumptions, such information is not a guarantee of future performance and actual results or developments may differ materially from those contained in forward-looking information. Factors that could cause actual results to differ materially from those in forward-looking information include, but are not limited to, fluctuations in market prices, successes of the operations of the Company, continued availability of capital and financing and general economic, market or business conditions. There can be no assurances that such information will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. The Company does not assume any obligation to update any forward-looking information except as required under the applicable securities laws.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Datametrex $DM.ca Receives Second COVID-19 Order from Film & TV Production Company

Posted by AGORACOM-JC at 9:11 AM on Wednesday, September 16th, 2020
Webinar logo
  • Received second Purchase Order (P.O.) for COVID-19 screening solutions with Lighthouse Pictures Inc., a Film and Television production company based in Vancouver, British Columbia
  • The service is scheduled to commence on September 16, 2020.
  • Datametrex anticipates that it will have little or no upfront costs associated with importing and selling these test kits

Toronto, Ontario–(September 16, 2020) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC: DTMXF) (the “Company” or “Datametrex”) is pleased to announce it has received second Purchase Order (P.O.) for COVID-19 screening solutions with Lighthouse Pictures Inc., a Film and Television production company based in Vancouver, British Columbia. The service is scheduled to commence on September 16, 2020. Datametrex anticipates that it will have little or no upfront costs associated with importing and selling these test kits.

Lighthouse Pictures is a company that specializes in producing genre and mid-to small-budget film and television projects. Industry leaders Shawn Williamson and Jamie Goehring helm Lighthouse Pictures. With over 65 productions in the past ten years, Lighthouse Pictures productions continue to be recognized. Year after year, Lighthouse projects have received industry praise with Canadian Screen Awards nominations, and numerous Leo Awards.

Vancouver is the third-largest production centre in North America, worth CDN $3.2 Billion during 2018/19, according to Creative BC. British Columbia is home to several world-class Film and TV studios, including Bridge Studios, Mammoth Studios, Vancouver Film Studios, North Shore Studios, Ironwood Studios, Canadian Motion Picture Park, and The Crossing Studios.

They all produce, on average, approximately 65+ movies and 55+ TV series annually, as well as hundreds of other filming days for commercials, TV pilots and other features. This industry generates over 42,000 direct and indirect jobs in Film and TV production, with more than 80 percent located in Metro Vancouver. British Columbia is world-renowned as a versatile and dependable hub for motion picture production.

Entire film and TV production in Canada represent $8.92 Billion in production volume, and full-time equivalent jobs represent 179,000 workers. In March 2020, the industry stopped in Vancouver, and the surrounding areas had 46 productions filming which does not include the TV commercial market. Each of the shows would have a minimum of a 100-person film crew. (source: https://www.creativebc.com/about-us/research-and-reports/index)

This demonstrates that Canada can be an advocate for the Film industry, as we have testing and labs already set up throughout. Additionally, Canada has far fewer instances of coronavirus with 139,146 cases, compared with more than 6,545,948 in the US, according to data compiled by Johns Hopkins University.

“With our pre-screening and screening tools, this industry can resume and provide us with the much-needed entertainment that this newly indoor, online-based culture requires”, said Marshall Gunter CEO of the Company.

These tools were developed as a direct response to customer needs and the ever-changing physical distancing recommendations, safety guidelines, and workplace flexibility initiatives being observed across North America and around the globe.

About Datametrex

Datametrex AI Limited is a technology-focused with exposure to Artificial Intelligence and Machine Learning through its wholly-owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.

For further information, please contact:
Marshall Gunter – CEO
Phone: (514) 295-2300
Email: [email protected]

Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not historical may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.

Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the time such forward-looking information is made. Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

###

Primo Nutraceuticals Inc. $PRMO.ca receives Medical Device Establishment License (MDEL) from Health Canada

Posted by AGORACOM-JC at 8:35 AM on Wednesday, September 16th, 2020
  • Announced it has been issued a Medical Device Establishment License (“MDEL”) from Health Canada
  • MDEL is a license issued to companies for the activities of manufacturing, importing and distributing (selling) of all four classes of medical devices for human use in Canada
  • These classes include; nitrile gloves, N95 surgical masks & KN95 masks, surgical gowns, respirators and testing kits to name a few

VANCOUVER, British Columbia, Sept. 16, 2020 — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVD) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo” or the “Company”) is pleased to announce it has been issued a Medical Device Establishment License (“MDEL”) from Health Canada.

The MDEL is a license issued to companies for the activities of manufacturing, importing and distributing (selling) of all four classes of medical devices for human use in Canada.

These classes include; nitrile gloves, N95 surgical masks & KN95 masks, surgical gowns, respirators and testing kits to name a few.

The MDEL license is issued by Health Canada’s Regulatory Operations and Enforcement Branch (ROEB) based on an attestation that the establishment meets all of HC’s MDEL regulatory requirements.

During an inspection by Health Canada, MDEL license holders must demonstrate to Health Canada that they meet the regulatory requirements attested to, having in place related medical devices that they intend to import and/or distribute (sell) in Canada.

Richard Cindric, CEO of Primo comments:

“Obtaining a Medical Device Establishment License is a milestone and a key step towards accessing the MDEL market share through the sale of already Health Canada approved commercialized devices. We have seen an increase in demand for PPE and medical devices since the COVID-19 pandemic surfaced. Receiving the MDEL license allows for more efficient, convenient and cost effective delivery of PPE and medical devices to Canadians including institutional markets and those managed by Federal and Provincial governments.”

Joel DeBellefeuille, Director of Primo comments: 

“The team has been working feverishly over the last few weeks focusing solely on delivering important catalysts. This one is definitely a major game-changer!”

About Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis natural health products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of the “Primo”  & “Thrive,” brands and a selection of curated partner brands. Most recently Primo announced that it has received its Natural Product Number (NPN) and it has been issued a Medical Device Establishment License (MDEL) from Health Canada.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

Andy Jagpal

Andy Jagpal
President and Director

For further information, please contact Zoltan, IR Representative at: 604-722-0305, or; [email protected].

To learn more about what this news means to the shareholders visit:

www.primonutraceuticals.com
www.twitter.com/Prmoinc
www.thrivecbd.com
www.mariannacorp.com
www.dcppe.net

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.No regulatory authority has approved or disapproved the information contained in this news release.

ECHL’s Allen Americans Select ImagineAR $IP.ca $IPNFF For Fan Engagement & Sponsorship Programs $SEV.ca $VST.ca $YDX.ca $NTAR.ca

Posted by AGORACOM-JC at 7:01 AM on Wednesday, September 16th, 2020
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg
  • Selected by the Allen Americans of the ECHL (Premier “AA” Hockey League)
  • The Allen Americans previously used ImagineAR to support local restaurant partners whose operations have been affected by the Coronavirus pandemic with the initiative, “Biscuit’s Curbside Pick Up”.
  • Neal Bendesky, VP Sports & Live Events of ImagineAR, said “The Allen Americans are leaders in the ECHL in leveraging ImagineAR to support their community partners. We are excited to extend their current AR partner program that activated their mascot Biscuit. Their new digital strategy will provide a more immersive experience for their fans that will create social media engagement.”

VANCOUVER, BC and ERIE, PA, Sept. 16, 2020 –ImagineAR Inc. (CSE: IP) (OTC: IPNFF), the company providing augmented reality (AR) fan engagement experiences for sports teams, announced they have been selected by the Allen Americans of the ECHL (Premier “AA” Hockey League).  The Allen Americans previously used ImagineAR to support local restaurant partners whose operations have been affected by the Coronavirus pandemic with the initiative, “Biscuit’s Curbside Pick Up”.

“The Allen Americans are excited to be expanding our ability to provide an iconic gameday atmosphere through the addition of this cutting-edge partnership with ImagineAR,” shares Allen Americans Team President and Alternate Governor Mike Waddell, “The immersive augmented reality engagements will deliver a new dimension of fan experiences with our Athletes, Coaches, Ice Angels and of course, the coolest dog on ice, Biscuit the Bulldog. The creativity is open ended so this ImagineAR technology will be continually evolving.”

Neal Bendesky, VP Sports & Live Events of ImagineAR, said “The Allen Americans are leaders in the ECHL in leveraging ImagineAR to support their community partners.  We are excited to extend their current AR partner program that activated their mascot Biscuit.  Their new digital strategy will provide a more immersive experience for their fans that will create social media engagement.”

About Allen Americans
The Allen Americans are the ECHL affiliate of the National Hockey League‘s Minnesota Wild and the American Hockey League‘s Iowa Wild. Championship Hockey is the backbone of the American’s franchise since being founded prior to the 2009-10 season, with the Red, White and Blue having captured two ECHL Kelly Cup Championships (2014-15 & 2015-16) and two Central Hockey League President’s Cups (2012-13 & 2013-14). Americans’ home games are played at the Allen Event Center, which is located in The Village at Allen. Owned by nationally respected “Serial Entrepreneur” Jack D. Gulati, the Club begins its 12th season of professional hockey in December 2020.  Season tickets are on sale now at AllenAmericans.com/tickets or by calling 972-912-1000.

About ImagineAR
Imagine AR Inc. (CSE: IP) (OTC: IPNFF) has developed ImagineAR.com; an “AR-as-a-Service” platform for desktops that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds using ImagineARTM. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage with videos, information, advertisements, coupons, 3D holograms and any interactive content, all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The ImagineAR.com mobile app is available in the IOS and Android mobile app stores.

For more information or to explore working with ImagineAR, please visit www.imaginear.com.

All trademarks of the property of respective owners.
ON BEHALF OF THE BOARD
Alen Paul Silverrstieen
President & CEO
(818) 850-2490
https://twitter.com/IPtechAR
https://www.facebook.com/imaginationparktechnologies
https://www.instagram.com/iptechar
https://www.linkedin.com/company/imagination-park-technologies-inc

We encourage you to do your own due diligence and ask your broker if Imagine AR  Inc. (CSE: IP) is suitable for your particular investment portfolio*.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward looking information is based on certain key expectations and assumptions made by ImagineAR’s management. Although ImagineAR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because ImagineAR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and ImagineAR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

CEO SPOTLIGHT: Iris Bincovich, CEO of Innocan Pharma $INNO.ca $WEED.ca $CL.ca $HEXO.ca $RWB.ca

Posted by AGORACOM-JC at 4:52 PM on Tuesday, September 15th, 2020
Innocan-Blog

Hub On AGORACOM / Corporate Profile

Else Nutrition $BABY.ca Announces $10 Million Bought Deal and Concurrent up to $5 million Private Placement $KMB $BMY $ABT $WYE

Posted by AGORACOM-JC at 4:14 PM on Tuesday, September 15th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • Entered into an agreement with Canaccord Genuity Corp. on behalf of a syndicate of underwriters pursuant to which the Underwriters have agreed to purchase, on a bought deal basis, an aggregate of 4,445,000 units of the Company at a price of $2.25 per Unit for aggregate gross proceeds to the Company of approximately C$10 million
  • In addition to the Offering, the Company is proposing to undertake a non-brokered private placement of up to 2,222,222 Units at the Offering Price for gross proceeds to the Company of up to C$5 million

VANCOUVER, BC, Sept. 15, 2020 – Else Nutrition Holdings (TSXV: BABY) (OTCQX: BABYF) (FSE: 0YL) (“Else” or the “Company”), is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. on behalf of a syndicate of underwriters (the “Underwriters”) pursuant to which the Underwriters have agreed to purchase, on a bought deal basis, an aggregate of 4,445,000 units (the “Units”) of the Company at a price of $2.25 per Unit (the “Offering Price”) for aggregate gross proceeds to the Company of approximately C$10 million (the “Offering”). 

Each Unit shall consist of one common share (each a “Common Share”) and one-half of one common share purchase warrant of the Company (each whole common share purchase warrant, a “Warrant”). Each Warrant shall be exercisable to acquire one common share of the Company (a “Warrant Share”) for a period of 24 months from closing of the Offering at an exercise price of C$3.25 per Warrant, subject to adjustment in certain events. 

The Company has granted the Underwriters an option (the “Over-Allotment Option”) to purchase up to an additional 666,750 Units at the Offering Price, which Over-Allotment Option will be exercisable at any time and from time-to-time, for a period of 30 days following the Closing Date (as defined below), which would result in additional gross proceeds of approximately $1.5 million. The Over-Allotment Option is exercisable to acquire Units, Common Shares and/or Warrants (or any combination thereof) at the discretion of the Underwriters. 

The Units will be offered by way of a short form prospectus to be filed in all provinces of Canada except Quebec and elsewhere on a private placement basis. The Offering is expected to close on October 6, 2020 (the “Closing Date”) and is subject to certain conditions including, but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the TSX Venture Exchange and the applicable securities regulatory authorities.

In addition to the Offering, the Company is proposing to undertake a non-brokered private placement of up to 2,222,222 Units at the Offering Price for gross proceeds to the Company of up to C$5 million (the “Concurrent Private Placement”).  No commission or finder’s fee is payable to the Underwriters in connection with the Concurrent Private Placement.

The Company intends to use the proceeds of the Offering for marketing, distribution, inventory and general corporate purposes.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.

About Else Nutrition Holdings Inc.
Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan.

The holding company, Else Nutrition Holdings Inc, is a publicly traded company, listed on the TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

TSX Venture Exchange
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements
This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include, but are not limited to, statements relating to the timing and ‎completion of the Offering, the satisfaction and timing of the receipt of required stock exchange ‎approvals and other conditions to closing of the Offering and the intended use of the net proceeds of ‎the Offering. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE Else Nutrition Holdings Inc.

Hospital ICUs lean on #telemedicine amid U.S. #COVID19 crisis – SPONSOR: MedX Health $MDX.ca $DMTK $ICAD $PLSE $SRTS

Posted by AGORACOM-JC at 9:35 AM on Tuesday, September 15th, 2020

SPONSOR: MedX Health Corporation (MDX:TSX-V) The company has commercialized a highly effective skin cancer scanning device. Patients can receive their prognosis and receive treatment within 72 hours after the initial screening. Initial orders from its Brazilian distribution partner could result in $8M of hardware sales over the next 2 years. Learn More.

Home - MedX Health

Hospital ICUs lean on telemedicine amid U.S. COVID-19 crisis

  • Camden is among a growing number of communities relying on this elaborate form of telemedicine to cope with an unrelenting COVID-19 case load and to manage unpredictable surges

By Chad Terhune

(Reuters) – As the coronavirus pandemic spreads deeper into America’s small towns and rural outposts, Dr. Tallulah Holmstrom has seen familiar faces fill her intensive-care unit in Camden, South Carolina.

A native of this hamlet of 7,000 people, Holmstrom saw its ICU threatened with closure in recent years as specialists departed for bigger cities. Now faraway doctors are helping treat the community’s COVID-19 patients, thanks to technology.

KershawHealth, the local hospital, installed cameras and other equipment for 24-hour monitoring by a company that employs doctors and nurses remotely. Sitting in cubicles in St. Louis, Houston and Honolulu, as well as other countries including Israel and India, these medical workers watch patients’ vital signs on computer screens and talk to local staff on two-way video about medications and treatments. KershawHealth employees can summon emergency help from these teleworkers by hitting a button on the wall.

Holmstrom said those changes, begun four years ago, have helped her hospital better handle the current crisis. While Camden and surrounding Kershaw County have seen more than 1,600 confirmed infections and 34 deaths, the technology has enabled many of the area’s COVID-19 patients to be hospitalized close to home.

“Now a patient can look up from their ICU bed here and they are seeing a friend’s daughter or son taking care of them or someone they go to church with,” said Holmstrom, chief medical officer at KershawHealth.

Camden is among a growing number of communities relying on this elaborate form of telemedicine to cope with an unrelenting COVID-19 case load and to manage unpredictable surges.

Well before the current crisis, vast stretches of rural America lacked easy access to advanced medical care. More than 130 rural hospitals have closed in the United States since 2010, including 18 last year, according to University of North Carolina researchers.

Rural areas tend to have higher rates of underlying health conditions such as diabetes and hypertension. Their populations often are older and poorer – making them more vulnerable to COVID-19.

Even if beds were available, qualified staff are hard to find. It’s estimated that 43 states, including South Carolina, face a shortage of highly trained ICU doctors, known as intensivists, according to researchers at George Washington University. These shortages may worsen with hospitalizations in many states predicted to peak this fall, when the coronavirus mixes with flu season, according to Patricia Pittman, director of the university’s Mullan Institute for Health Workforce Equity.

“No one is suggesting telemedicine is ideal, but it’s probably one of the least bad options,” she said. “It is definitely better than having no one and helicoptering people out.”

SCALING EXPERTISE

About a third of U.S. hospitals surveyed in 2017 said they had access to a formal program of telemedicine for critically ill patients. Studies have shown telemedicine can benefit ICU patients by promoting the best practices supported by medical evidence and by reducing complications. During the pandemic, doctors say, it has helped conserve personal protective equipment and reduce workers’ exposure to the virus.

There can be drawbacks, too, if physicians try to monitor too many people at once, which can lead to poor decisions or even medical errors. Tele-ICU generally requires physicians working remotely to hold a license in each state where people are hospitalized.

The Trump administration has eased rules on telehealth during the pandemic and expanded reimbursement by Medicare. Shares of telemedicine companies such as Teladoc Health Inc have soared as patients embraced online visits.

Sutter Health, a large hospital system in California, said it manages more than 300 ICU beds across 18 hospitals from offices in Sacramento and San Francisco.

Earlier this month at its Sacramento hub, Dr. Vanessa Walker checked in remotely on a patient who was taken off a ventilator earlier in the day at Sutter’s Roseville hospital about 25 miles away. Using a headset and camera, she clicked the patient’s name on her screen, which rang a doorbell to notify the patient that she was entering the room via video.

“Save your breath. You’re doing well otherwise,” she told the patient.

Walker, the medical director of Sutter’s electronic ICU for its hospitals in California’s Central Valley, had a wide array of information across six monitors at her desk. She could review medical records and see multiple scans of the patient’s lungs before and after treatment.

CAUTIONARY TALE

As use of this technology grows, patient-safety advocates warn hospitals not to cut corners. They say cameras and computers are no substitute for trained professionals at the bedside who can respond rapidly to life-threatening complications.

The Leapfrog Group, a nonprofit that monitors patient safety, recommends that a physician certified in critical care medicine perform an in-person review of each ICU patient daily before handing off monitoring to colleagues remotely. The group says remote doctors should lower their patient loads if they can’t respond within five minutes to requests from on-site staff and evaluate the patient.

Steve Burrows, a Los Angeles filmmaker, remains a skeptic.

He said his mother had complications during a hip operation in 2009 and suffered permanent brain damage in surgery and the ICU at a Wisconsin hospital.

In litigation, Burrows said, he learned that a doctor was remotely monitoring more than 150 ICU patients, and there was no physician in the ICU who could respond to his mother’s low blood pressure. He released an HBO documentary, “Bleed Out,” in 2018 about his mother’s case.

“Telemedicine is fantastic if it’s used properly,” he said in an interview. “But I think replacing doctors at the bedside with technology is insane.”

At trial, a jury found there was no negligence by the hospital. Advocate Aurora Health, the current hospital owner after a merger, said its electronic ICU “does not replace bedside caregivers. Instead, it serves as an additional set of eyes that provides an extra layer of safety.”

‘CONSTANT ATTENTION’

Advanced ICU Care, the St. Louis company serving Camden, works with more than 90 hospitals in 26 states. Overall, it has treated more than 1,300 COVID-19 patients.

“These patients need constant attention and continuous adjustments. That is a lot of what we do,” said Dr. Ram Srinivasan, the company’s chief medical officer.

South Carolina remains a hot spot for coronavirus infections with more than 126,000 cases and 2,877 confirmed deaths as of September 11.

The state’s first two cases of COVID-19 were announced the same day in early March and one was in Camden, a place so rural that signs remind people not to ride horses on the sidewalk.

Holmstrom, the chief medical officer at KershawHealth, got a call with the news while driving home that Friday, March 6. Within a matter of days, there were six people infected and four were hospitalized.

The Camden ICU was nearly full for weeks as the medical staff juggled COVID-19 patients alongside the normal flow of critically ill people. Hospitalizations eased around Memorial Day, Holmstrom said, only to surge again in July and much of August.

“When you’re a town this small and 32 people get sick in one day that’s a lot,” said Vic Carpenter, Kershaw County administrator.

Holmstrom, who was born in the hospital where she now works, has experienced highs and lows. A close friend who spent six weeks in the hospital is now back to full strength. Holmstrom arranged final video calls for others to say goodbye to their families.

KershawHealth is bracing for another surge this fall, when it once again will turn to remote doctors to back up busy hospital staff.

“It’s like someone constantly in the background overlooking everything with your care,” Holmstrom said.

(Reporting by Chad Terhune in Los Angeles; Additional reporting by Nathan Frandino in Sacramento; Editing by Marla Dickerson)

Source: https://www.thechronicleherald.ca/news/world/hospital-icus-lean-on-telemedicine-amid-us-covid-19-crisis-496573/